142 related articles for article (PubMed ID: 17594597)
1. Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases.
Mahta A; Haghpanah V; Lashkari A; Heshmat R; Larijani B; Tavangar SM
Folia Neuropathol; 2007; 45(2):72-7. PubMed ID: 17594597
[TBL] [Abstract][Full Text] [Related]
2. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
[TBL] [Abstract][Full Text] [Related]
3. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
4. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.
Pizarro CB; Oliveira MC; Coutinho LB; Ferreira NP
Braz J Med Biol Res; 2004 Feb; 37(2):235-43. PubMed ID: 14762579
[TBL] [Abstract][Full Text] [Related]
5. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
6. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
7. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
8. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
[TBL] [Abstract][Full Text] [Related]
9. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
10. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
Mastronardi L; Guiducci A; Puzzilli F
BMC Cancer; 2001; 1():12. PubMed ID: 11570981
[TBL] [Abstract][Full Text] [Related]
12. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas.
Losa M; Ciccarelli E; Mortini P; Barzaghi R; Gaia D; Faccani G; Papotti M; Mangili F; Terreni MR; Camanni F; Giovanelli M
J Clin Endocrinol Metab; 2001 Nov; 86(11):5194-200. PubMed ID: 11701676
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody.
Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Maira G
J Clin Pathol; 1999 Feb; 52(2):107-11. PubMed ID: 10396237
[TBL] [Abstract][Full Text] [Related]
14. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and growth fractions of pituitary adenomas.
Yonezawa K; Tamaki N; Kokunai T
Surg Neurol; 1997 Nov; 48(5):494-500. PubMed ID: 9352815
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
17. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas.
Jaffrain-Rea ML; Di Stefano D; Minniti G; Esposito V; Bultrini A; Ferretti E; Santoro A; Faticanti Scucchi L; Gulino A; Cantore G
Endocr Relat Cancer; 2002 Jun; 9(2):103-13. PubMed ID: 12121834
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of estrogen receptor alpha in pituitary adenomas and its correlation with cellular replication.
Pereira-Lima JF; Marroni CP; Pizarro CB; Barbosa-Coutinho LM; Ferreira NP; Oliveira MC
Neuroendocrinology; 2004 Mar; 79(3):119-24. PubMed ID: 15103224
[TBL] [Abstract][Full Text] [Related]
19. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.
Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S
J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623
[TBL] [Abstract][Full Text] [Related]
20. FSH secretion predominates in vivo and in vitro in patients with non-functioning pituitary adenomas.
Hanson PL; Aylwin SJ; Monson JP; Burrin JM
Eur J Endocrinol; 2005 Mar; 152(3):363-70. PubMed ID: 15757852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]